A Market Charging More For Risk
The S&P 500 fell 0.9% Thursday, its fourth decline in the five sessions since last week’s record high. The Nasdaq Composite lost 1%, and the Russell 2000 fell 1.3%. Through Thursday, the S&P was down 1.9% for the week, while both the Nasdaq and Russell were down 2.5%.
Higher discount rates and energy costs did most of the macro damage. The 10-year Treasury yield rebounded to 4.70%, and Brent crude rose 2.4% to $93.78 as Iran-related uncertainty returned to the foreground. Those aren’t friendly inputs for richly valued growth stocks or consumer spending.
Walmart (WMT 0.00%↑) supplied the company-level warning. Its shares fell 9.2%, their worst day in four years, after U.S. comparable sales rose 2.6%—the slowest pace in more than six years—and its current-quarter profit outlook disappointed. That left the market dealing with an awkward combination: a more cautious consumer, dearer oil, and a bond market again demanding more yield.
Proof Still Gets Paid
Company-specific catalysts still commanded enormous premiums. On Wednesday, Moderna (MRNA 0.00%↑) surged 177% after its personalized messenger RNA (mRNA) melanoma treatment with Merck (MRK 0.00%↑) met both key endpoints in a Phase 3 trial. Twist Bioscience (TWST 0.00%↑) jumped about 17% after Anthropic reported that Claude had designed successful protein binders against 14 of 15 targets, with Twist helping produce and validate them in the lab. Moderna gave back part of Wednesday’s move Thursday, but the larger signal remained intact: credible proof can still overpower a weak tape.
That’s the kind of market in which bottom-up selection matters most. The broad indexes are absorbing pressure from yields, oil, and consumer weakness, while individual companies can still reprice sharply when earnings, clinical data, or technological validation changes the story. Portfolio Armor’s rankings don’t require us to predict which macro pressure eases first; they show us where estimated six-month returns are clustering now.
Tonight’s Top Names show where that strength is clustering. Nine of the ten are tied to the technology stack—semiconductors, storage, cloud observability, or cybersecurity—with the two highest-ranked securities each carrying an estimated potential return of 86%. The lone biopharmaceutical name fits a second source of strength this week, when clinical validation and AI-enabled protein design drove some of the market’s sharpest single-stock moves.
Next week, we’ll watch whether those technology leaders can hold their technical support while yields stay near recent highs, and whether the biotech bid broadens beyond this week’s catalysts.
Our Basic Strategy
Our basic strategy is to buy equal dollar amounts of the Portfolio Armor web app’s top ten names, put trailing stops of ~20% or more on them, and replace them with names from the current week’s top ten when we get stopped out of a position—there are no options involved in this strategy.
Another Use For Our Top Names
We also use our top names in options trades, such as this one we exited this week:
A Top Names Performance Update
Before we get to this week’s top ten names, let’s look at the final, 6-month performance of our top ten names from February 19th.
Over the next 6 months, our top ten names from February 19th, 2026 returned +22.15%, versus +12.35% for the SPDR S&P 500 Trust ETF (SPY 0.23%↑).
So far, we have 6-month returns for 164 weekly top names cohorts since we started this Substack at the end of December, 2022.
[Skipping ahead so this post doesn’t exceed email length—you can see the top names returns for every week here]
And as you can see above, our top names have averaged returns of 17.67% over the next six months, versus SPY’s average of 9.70%. You can see an interactive version of the table above here, where you can click on each date and see a chart showing each of the holdings that week.
This Week’s Top Names
Below are Portfolio Armor’s current top ten names as of Thursday’s close.
